Login to Your Account



As It Focuses On Xyotax, CTI Selling Trisenox To Cephalon

By Karen Pihl-Carey


Tuesday, June 14, 2005
After disappointing Phase III data for the lung cancer drug Xyotax, Cell Therapeutics Inc. has sold its one marketed product - Trisenox - to Cephalon Inc. for up to $170 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription